Advertisement

Therapeutic Potential of Yersinia Anti-Inflammatory Components

  • Benoit Foligné
  • Joëlle Dewulf
  • Bruno Pot
  • Catherine Daniel
  • Michel Simonet
  • Sabine Poiret
  • Michaël Marceau
  • Rodrigue Dessein
Part of the Advances In Experimental Medicine And Biology book series (AEMB, volume 603)

Microbial pathogens have developed various stratagems for modulating and/or circumventing the host’s innate and adaptive immunity. Hence, certain virulence factors can be viewed as potential therapeutic agents for human immunopathological diseases. This is the case for virulence plasmid-encoded proteins from pathogenic Yersiniae that inhibit the host’s inflammatory response by interfering with various cellular signaling pathways.

Keywords

Inflammatory Bowel Disease Ulcerative Colitis Inflammatory Bowel Disease Therapy Pathogenic Yersinia TNBS Administration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abad, C., Juarranz, Y., Martinez C., Arranz A., Rosignoli, F., Garcia-Gomez, M., Leceta, J. and Gomariz, R.P. (2005) DNa array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. Inflamm. Bowel Dis. 11, 674-684.CrossRefPubMedGoogle Scholar
  2. Bouma, G. and Strober, W. (2003) The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3, 521-533.CrossRefPubMedGoogle Scholar
  3. Braat, H., Rottiers, P., Hommes, D.W., Huyghebaert, N., Remaut, E., Remon, J.P., van Deventer, S.J., Neirynck, S., Peppelenbosch, M.P. and Steidler, L. (2006) A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin. Gastroen-terol. Hepatol. 4, 754-759.CrossRefGoogle Scholar
  4. Brubaker, R.R. (2003) Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and Lcrv (V antigen). Infect. Immun. 71, 3673-3681.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Foligné, B., Nutten, S., Steidler, L., Dennin, V., Goudercourt, D., Mercenier, A. and Pot, B. (2006) Recommendations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria: technical and microbi-ological aspects. Dig. Dis. Sci. 51, 390-400.CrossRefPubMedGoogle Scholar
  6. Korzenik, J.R. and Podolsky, D.K. (2006) Evolving knowledge and therapy of inflammatory bowel disease. Nat. Rev. Drug Discov. 5, 197-209.CrossRefPubMedGoogle Scholar
  7. Le Loir, Y., Azevedo, V., Oliveira, S.C., Freitas, D.A., Miyoshi, A., Bermudez-Humaran, L.G., Nouaille, S., Ribeiro, L.A., Leclercq, S., Gabriel, J.E., Guimaraes, V.D., Oliveira M.N., Charlier, C., Gautier, M. and Langella P. (2005) Protein secretion in Lactococcus lactis: an efficient way to increase the overall heterologous protein production. Microb. Cell. Fact. 4, 2.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Marceau, M., Dubuquoy, L., Caucheteux-Rousseaux, C., Foligné, B., Desreumaux, P. and Simonet, M. (2004) Yersinia pseudotuberculosis anti-inflammatory components reduce trinitrobenzene sulfonic acid-induced colitis in the mouse. Infect. Immun. 72, 2438-2441.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Nakajima, R., Motin, V.L. and Brubaker, R.R. (1995). Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunization. Infect. Immun. 63, 3021-3029.PubMedPubMedCentralGoogle Scholar
  10. Podolsky, D.K. (2002) Inflammatory bowel disease. N. Engl. J. Med. 347, 417-429.CrossRefPubMedGoogle Scholar
  11. Sing, A., Rost, D., Tvardovskaia, N., Roggenkamp, A., Wiedemann, A., Kirschning, C.J., Aepfelbacher, M. and Heesemann, J. (2002) Yersinia V-antigen exploits toll-like recep tor 2 and CD14 for interleukin 10-mediated immunosuppression. J. Exp. Med. 196, 1017-1024.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Viboud, G.I. and Bliska J. B. (2005) Yersinia outer proteins: role in modulation of host cell signaling responses and pathogenesis. Annu. Rev. Microbiol. 59, 69-89.CrossRefPubMedGoogle Scholar
  13. Wallace, J.L., MacNaughton, W.K., Morris, G.P. and Beck, P.L. (1989) Inhibition of leukot-riene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 96, 29-36.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Benoit Foligné
    • 1
  • Joëlle Dewulf
    • 2
  • Bruno Pot
    • 2
  • Catherine Daniel
    • 2
  • Michel Simonet
    • 1
  • Sabine Poiret
    • 2
  • Michaël Marceau
    • 1
  • Rodrigue Dessein
    • 1
  1. 1.Faculté de Médecine, Institut Pasteur de LilleUniversité de LilleInsermFrance
  2. 2.Laboratoire des Bactéries Lactiques et Immunité des MuqueusesInstitut Pasteur de LilleFrance

Personalised recommendations